Loading...
OTC Markets
Totals
Securities
12,214
Dollar Vol
$2.7B
Share Vol
3.1B
Trades
358,241

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

ANPCY
ANGLE plc

Sponsored ADR (1 ADS : 10 Ordinary)

0.87205

0.15775

22.08%

0.7818 / 0.9619 (1000 x 1000)

Real-Time Best Bid & Ask: 05:00pm 07/18/2025
Delayed (15 Min) Trade Data: 12:00am 07/18/2025

ANGLE plc

10 Nugent Road

Surrey Research Park, Guildford

Surrey, ENG GU2 7AF

United Kingdom

Principal Executive Offices:

10 Nugent Road

Surrey Research Park, Guilford

Surrey, ENG GU2 7AF

United Kingdom

Business Description
ANGLE is a world leading liquid biopsy company with pioneering products and services in cancer diagnostics. ANGLE's lead product is the Parsortix cell separation system, which captures very rare cells from blood including circulating tumour cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalised cancer care. ANGLE sells instruments and cassettes for RUO only worldwide and also sells IVD product for use in metastatic breast cancer (MBC) - the Parsortix PC1 Clinical System is FDA cleared for its intended use in MBC and is ...
More
Financial Reporting
Reporting Status
International Reporting: LSE - London Stock Exchange | Alternative Investment Market (AIM)
Audited Financials
Audited
CIK
0001620678
Fiscal Year End
12/31
Company Officers & Contacts
Andrew Newland
CEO

Andrew Newland is Chief Executive of ANGLE plc. He has an MA in Engineering Science from the University of Cambridge and is a qualified Chartered Accountant. He has over 20 years of medical diagnostics experience and has specialised in the liquid biopsy space for the last 14 years. Andrew has led the development of technology-based businesses based on strong intellectual property for over 30 years and for the last 20 years he has been Chairman, or on the Board of several specialist medical technology companies. After working with the engineering conglomerate TI plc, Andrew worked for KPMG from 1982 to 1994 and during this time provided corporate finance and business advice to technology firms. In 1994, Andrew founded ANGLE with the goal of developing and commercialising technologies that enable precision medicine and translational research. Andrew has overseen the launch and regulatory filings of the Company's flagship rare cell separation and capture liquid biopsy device, the Parsortix system which culminated in the US Food and Drug Administration approval for the Parsortix PC1 system in 2022 and subsequent EU and UK medical device regulatory approvals. Brings to the Board Over 30 years' experience establishing, leading and building technology-based businesses, over 20 years leading specialist MedTech businesses, and 14 years in the liquid biopsy space.

Ian F Griffiths
CFO

Ian Griffiths is the Chief Financial Officer of ANGLE plc. He has specialised in technology commercialisation for over 30 years and is an expert on the development and growth of new technology-based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy with a special work focus, then in management consulting within KPMG's High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. Ian joined ANGLE in 1995. As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the former UK, US and Middle East Consulting and Management services businesses and in developing new Ventures, both third-party and ANGLE's own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE's own ventures by working closely with management on business plans, financial and operational management, fundraising and commercial aspects, including both medical and physical sciences companies. Ian led the financial aspects of ANGLE plc listing on the Alternative Investment Market. Brings to the Board Over 30 years' experience in finance and technology-based businesses, and 14 years in the liquid biopsy space.

Board of Directors
Jan Groen
Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Dr. Jan Groen's career spans over 25 years in clinical diagnostics and life science global markets. Jan is the former CEO and Chairman of the board at Intravacc B.V., a contract development and manufacturing organisation for infectious disease and therapeutic vaccines in the Netherlands. Jan was previously the President and CEO of MDxHealth, a Euronext listed genomic diagnostics company that reduces diagnostic ambiguity in urological cancers. Prior to this Jan was the President and COO of Agendia, responsible for their United States and European diagnostic operations, respectively. Jan is co-founder of Viroclinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, and Akzo-Nobel. Jan has had board mandates in several diagnostic companies. Currently he serves on the board of Novigenix SA in Switzerland, SPL Medical and Delta Diagnostics, both in the Netherlands. Jan holds a PhD degree in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics. Jan joined ANGLE as a Non-executive Director in November 2018 and became Chairman in May 2023. Brings to the Board Expertise in new product development, including development and successful commercialisation of CE marked and FDA cleared diagnostic products and LDTs.

Brian Howlett
Non-Executive Director, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Brian Howlett has a wealth of international experience as a MedTech leader in a Non-executive/Chairman capacity for medical device coating and surface modification company Accentus Medical Ltd, as well as ANGLE plc. Brian was formerly CEO of Lombard Medical Technologies PLC, an AIM listed company specialising in stents for abdominal aortic aneurysms, from 2005 to 2009. During his tenure significant capital was raised to fund the development of operations to commercialise the Aorfix stent graft towards regulatory approvals and growing revenues in the EU, USA, Russia and Brazil. Brian recently retired from the Board of neuro-endovascular company Oxford Endovascular Ltd. Corporate experience includes six years as UK Country Leader of Boston Scientific Ltd, between 1999 and 2005, during which time major medical devices such as the TAXUS drug eluting stent were launched driving sales and profits to the point where the UK and Ireland subsidiary became one of the leading revenue contributors to the corporation's European operations. Between 1987 and 1999, Brian was Managing Director of the UK sales and manufacturing subsidiary of Cobe Laboratories Inc. In addition, Brian spent almost 20 years in the pharmaceutical industry, gaining strong sales and marketing experience through a number of senior management positions in the UK, Scandinavia and Benelux markets within Fisons plc. Brings to the Board Extensive commercial operations experience of the MedTech sector.

Joseph Eid
Non-Executive Director, Independent Director, Compensation Committee Member, Nominating Committee Member

Dr. Joseph Eid is a qualified physician, board certified in medical oncology, haematology and internal medicine. He is a highly experienced pharmaceutical industry executive with over 25 years of proven expertise in people and portfolio management, planning, designing and executing Phase I to IV clinical trials and building and managing clinical and medical affairs teams and strategies. He has successfully designed and implemented clinical development, medical affairs and life cycle management plans for pharmaceutical products including cytotoxic agents, monoclonal antibodies, immune-oncology agents, antibody-drug conjugates and CAR-T cell therapies. His previous experience includes senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche. Whilst at Merck, Joe led the global Keytruda (pembrolizumab, MK-3475, immune checkpoint inhibitor) first-in-human strategy, including oversight of the clinical, regulatory and manufacturing planning and execution and development of the PD-L1 biomarker strategy on tissue biopsy, which led to a first-in-class anti-PD-1 BLA filing and approval in the US. Brings to the Board Valuable knowledge and experience in oncology drug development and the use of biomarkers in the clinical trials process and as companion diagnostics.

Andrew Newland
CEO

Andrew Newland is Chief Executive of ANGLE plc. He has an MA in Engineering Science from the University of Cambridge and is a qualified Chartered Accountant. He has over 20 years of medical diagnostics experience and has specialised in the liquid biopsy space for the last 14 years. Andrew has led the development of technology-based businesses based on strong intellectual property for over 30 years and for the last 20 years he has been Chairman, or on the Board of several specialist medical technology companies. After working with the engineering conglomerate TI plc, Andrew worked for KPMG from 1982 to 1994 and during this time provided corporate finance and business advice to technology firms. In 1994, Andrew founded ANGLE with the goal of developing and commercialising technologies that enable precision medicine and translational research. Andrew has overseen the launch and regulatory filings of the Company's flagship rare cell separation and capture liquid biopsy device, the Parsortix system which culminated in the US Food and Drug Administration approval for the Parsortix PC1 system in 2022 and subsequent EU and UK medical device regulatory approvals. Brings to the Board Over 30 years' experience establishing, leading and building technology-based businesses, over 20 years leading specialist MedTech businesses, and 14 years in the liquid biopsy space.

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
PricewaterhouseCoopers LLP

1 Embankment Place

London WC2N 6RH

United Kingdom

Investment Bank
Berenberg

60 Threadneedle Street

London, ENG EC2R 8HP

United Kingdom

Investor Relations/Marketing/Communications
FTI Consulting

200 Aldersgate

Aldersgate Street

London, ENG EC1A 4HD

United Kingdom

Securities Counsel
Linklaters LLP

One Silk Street

London EC2Y 8HQ

United Kingdom

Securities Counsel
Pinsent Masons LLP

30 Crown Place

Earl Street

London, ENG EC2A 4ES

United Kingdom

Profile Data
SIC - Industry Classification
8099 - Health and allied services, misc
Incorporation Information
GB, 2004
Employees
121 as of 05/29/2025
Shell
No
Products and Services

Services business area: The primary commercialisation route for the Parsortix system, assays and workflows, is through partnership with large pharma, where liquid biopsy assays can support drug discovery and development with a view to adoption as a companion diagnostic to support optimal use of their cancer drugs. ANGLE has developed bespoke imaging assays to meet our customers’ needs and can offer state-of-the art molecular assays which leverage the rapid technological advancements in sequencing and AI. This is enabling the analysis of CTCs with increasing throughput and sensitivity. Product business area: Parsortix PR1 (Research Use Only) Instrument and cassettes for the harvesting of circulating tumor cells. Parsortix PC1 (Clinical) for the harvesting of CTCs in metastatic breast cancer - the end user is responsible for the validation of any downstream assay. ANGLE’s sales of the Parsortix system, assays and consumables to independent cancer centres and research institutes continues to drive breakthrough research and first-in-class discoveries which may flow through into commercial drug development.

Company Facilities

Rent/lease lab/office properties in two main locations 1) 10 Nugent Road and 2 Occam Court, Surrey Research Park, Guildford, UK 2) 5100 Campus Drive, Suite 100, Plymouth Meeting, PA 19462, USA. The UK facility has both an R&D lab and a clinical lab, with Parsortix instruments to harvest the CTCs and associated equipment for downstream analysis in both imagining (FISH, IF) and molecular (dPCR and Illumina NGS).

Company Notes
Sponsored for OTCQX by BNY Mellon on 10/31/2014.
Formerly=Angle Plc. until 10-2014
OTCQX Best Market Logo
Joined OTCQX 10/2014
The Company Profile data was verified by the issuer within the previous 6 months.
This security is not a Penny Stock as defined in SEC Rule 240.3a51-1.
This company has certified to OTC Markets Group that it is eligible to rely on the exemption from registration under Securities and Exchange Act Rule 12g3-2(b).
The Company’s board of directors includes at least two Independent Directors.
Securities
Other ANGLE plc Securities
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.